- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02768077
Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease
May 16, 2016 updated by: Kuhnil Pharmaceutical Co., Ltd.
Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial
This clinical study is a double-blind, randomized, placebo-controlled trial to investigate the effects of melatonin on the sleep disturbance symptoms of Parkinson's disease patients, symptoms which have a significant impact on the quality of life of these patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
After selecting patients who satisfied the inclusion criteria and were not disqualified by the exclusion criteria, through a double-blind procedure the patients are directed to orally take either the investigational drug melatonin or a placebo(allocation ratio 1:1) for 4 weeks, once daily, before going to sleep.
The evaluation of efficacy and safety is performed at the first baseline and immediately after administering the drug for 4 weeks.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
53 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who meet the clinical criteria for idiopathic Parkinson's disease (United Kingdom Parkinson's Disease Brain Bank Criteria)
- Patients who complain of sleep disturbances such as insomnia, REM sleep behavior disorder, excessive daytime sleepiness (EDS), etc.
- Patients who have received drug treatment for at least 6 months since their diagnosis
- Male or female patient aged 55 or older
- Patients who have given voluntary consent after understanding the content of the clinical trial (in the case of elderly patients aged 70 or older, consent must be received from both the subject and the his or her legal representative)
Exclusion Criteria:
- Patients with a serious cognitive disorder, behavioral disorder, or mental illness
Patients with a serious medical disease
- Patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, moderate or more severe liver disease
- Patients with un-controlled high blood pressure or diabetes
- Patients who have taken another drug under clinical trial within 4 weeks prior to registering for this clinical trial, or patients who are pregnant or breastfeeding
- Patients who have a history of hypersensitivity to the investigational drug or a drug similar in component or who have had heavy metal poisoning
- Patients who are taking drugs which could effect on sleep such as rivotril, quetiapine, lexapro, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Melatonin(Circadin®)
Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
|
Other Names:
|
Placebo Comparator: Placebo
Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variation in PSQI(Pittsburgh Sleep Quality Index)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variations in RBDQ(The REM sleep Behavior Disorder screening Questionnaire)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in PDSS(The Parkinson's Disease Sleep Scale)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in ESS(The Epworth Sleepiness Scale)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in UPDRS(Unified Parkinson Disease Rating Scale)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in H & Y Scale(Hoehn and Yahr Scale)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in NMSS(Non-Motor Symptom assessment Scale)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in PDQ-39(The 39-Item Parkinson's Disease Questionnaire)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variations in CGI(Clinical Global Impression)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Variations in PGI(Patient Global Impression)
Time Frame: Baseline and immediately after administering the drug for 4 weeks
|
Baseline and immediately after administering the drug for 4 weeks
|
Number of subjects with adverse events
Time Frame: 4 weeks of drug treatment
|
4 weeks of drug treatment
|
Number of subjects with serious adverse events
Time Frame: 4 weeks of drug treatment
|
4 weeks of drug treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eungseok Oh, Chungnam National University Hospital, Department of Neurology
- Principal Investigator: Wooyoung Jang, Gangneung Asan Hospital, Department of Neurology
- Principal Investigator: Jinse Park, Inje University Haeundae Paik Hospital, Department of Neurology
- Principal Investigator: Jisun Kim, Soon Chun Hyang University Hospital, Department of Neurology
- Principal Investigator: Jin Whan Cho, Samsung Medical Center, Department of Neurology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Anticipated)
February 1, 2017
Study Completion (Anticipated)
February 1, 2017
Study Registration Dates
First Submitted
May 9, 2016
First Submitted That Met QC Criteria
May 9, 2016
First Posted (Estimate)
May 11, 2016
Study Record Updates
Last Update Posted (Estimate)
May 18, 2016
Last Update Submitted That Met QC Criteria
May 16, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Sleep Wake Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Dyssomnias
- Parasomnias
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Antioxidants
- Melatonin
Other Study ID Numbers
- Circadin-2015-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States